

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2018282427 C1**

(54) Title  
**COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 AD-  
RENORECEPTOR AGONIST**

(51) International Patent Classification(s)  
**A61K 31/138** (2006.01) **A61P 11/06** (2006.01)  
**A61K 31/439** (2006.01) **A61P 11/08** (2006.01)  
**A61K 45/06** (2006.01)

(21) Application No: **2018282427** (22) Date of Filing: **2018.12.21**

(43) Publication Date: **2019.01.17**

(43) Publication Journal Date: **2019.01.17**

(44) Accepted Journal Date: **2021.04.01**

(44) Amended Journal Date: **2022.06.30**

(62) Divisional of:  
**2016262698**

(71) Applicant(s)  
**Glaxo Group Limited**

(72) Inventor(s)  
**Baker, Darrell; Bruce, Mark; Crater, Glenn; Noga, Brian; Thomas, Marian; Wire, Patrick**

(74) Agent / Attorney  
**Phillips Ormonde Fitzpatrick, PO Box 323, COLLINS STREET WEST, VIC, 8007, AU**

(56) Related Art  
**WO 2003024439 A1**  
**WO 2005104745 A2**  
**GlaxoSmithKline, ClinicalTrials.gov [online], NCT00976144, 11 September 2009,**  
**<URL: [https://clinicaltrials.gov/ct2/history/NCT00976144?V\\_1](https://clinicaltrials.gov/ct2/history/NCT00976144?V_1)>**  
**KELLEHER D.L. et al., PLOS ONE, 2012, vol. 7, no. 12, e50716, doi:10.1371/  
journal.pone.0050716**